γ-diketones as Wnt/β-catenin signaling pathway activators
The present disclosure provides γ-diketones or analogs thereof, that activate Wnt/β-catenin signaling and thus treat or prevent diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries or spine injuries, brain atrophy/neurological disorders related to the differentiation and development of the central nervous system, including Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia; otic disorders like cochlear hair cell loss; eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, such as hair loss, hematopoiesis related diseases and tissue regeneration related diseases.
1. A compound having a structure:
or a pharmaceutically acceptable salt thereof.
2. A pharmaceutical composition comprising a compound having a structure:
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
3. The pharmaceutical composition of claim 2 , wherein the pharmaceutically acceptable excipient is selected from the group consisting of: a polyethylene glycol, a partial glyceride mixture of saturated vegetable fatty acids, a triglyceride, a glycol, a glycerol, and mixtures thereof.
4. The pharmaceutical composition of claim 2 , wherein the pharmaceutical composition is a solid composition.
5. The pharmaceutical composition of claim 2 , wherein the pharmaceutical composition is a liquid composition.
6. The pharmaceutical composition of claim 2 , wherein the pharmaceutical composition is an emulsion.
7. The pharmaceutical composition of claim 2 , wherein the pharmaceutical composition is formulated for topical administration.
8. The pharmaceutical composition of claim 2 , wherein the pharmaceutical composition is formulated for oral administration.
9. The pharmaceutical composition of claim 2 , wherein the pharmaceutical composition comprises about 0.05 to about 3% by weight of the compound or pharmaceutically acceptable salt thereof.
10. The pharmaceutical composition of claim 2 , wherein the pharmaceutical composition comprises about 0.02 to about 2% by weight of the compound or pharmaceutically acceptable salt thereof.
11. A topical composition comprising a compound having a structure:
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
12. The topical composition of claim 11 , wherein the pharmaceutically acceptable excipient is selected from the group consisting of: a polyethylene glycol, a partial glyceride mixture of saturated vegetable fatty acids, a triglyceride, a glycol, a glycerol, and mixtures thereof.
13. The topical composition of claim 11 , wherein the composition comprises about 0.05 to about 3% by weight of the compound or pharmaceutically acceptable salt thereof.
14. The topical composition of claim 11 , wherein the composition comprises about 0.02 to about 2% by weight of the compound or pharmaceutically acceptable salt thereof.
15. A method of treating hair loss, the method comprising administering to a patient a therapeutically effective amount of the compound or pharmaceutically acceptable salt thereof of claim 1 .
16. A method of treating hair loss, the method comprising administering to a patient a therapeutically effective amount of the pharmaceutical composition of claim 2 .
17. A method of treating hair loss, the method comprising administering to a patient a therapeutically effective amount of the topical composition of claim 11 .